دورية أكاديمية
أعرض في EDS

MicroRNA-181a restricts human γδ T cell differentiation by targeting Map3k2 and Notch2.

التفاصيل البيبلوغرافية
العنوان: MicroRNA-181a restricts human γδ T cell differentiation by targeting Map3k2 and Notch2.
المؤلفون: Gordino G; Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal., Costa-Pereira S; Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal., Corredeira P; Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal., Alves P; Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal., Costa L; Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.; Medical Oncology Division, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal., Gomes AQ; Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.; Escola Superior de Tecnologia da Saúde de Lisboa, Lisbon, Portugal., Silva-Santos B; Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal., Ribot JC; Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
المصدر: EMBO reports [EMBO Rep] 2022 Jan 05; Vol. 23 (1), pp. e52234. Date of Electronic Publication: 2021 Nov 24.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 100963049 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1469-3178 (Electronic) Linking ISSN: 1469221X NLM ISO Abbreviation: EMBO Rep Subsets: MEDLINE
أسماء مطبوعة: Publication: 2024- : [London] : Nature Publishing Group
Original Publication: Oxford, UK : Published for EMBO by Oxford University Press, 2000-
مواضيع طبية MeSH: Cell Differentiation* , MicroRNAs*/genetics , Receptor, Notch2*/metabolism, T-Lymphocytes/*cytology, Humans ; Lymphocyte Activation ; MAP Kinase Kinase Kinase 2/metabolism ; Male ; Prostatic Neoplasms ; Signal Transduction
مستخلص: γδ T cells are a conserved population of lymphocytes that contributes to anti-tumor responses through its overt type 1 inflammatory and cytotoxic properties. We have previously shown that human γδ T cells acquire this profile upon stimulation with IL-2 or IL-15, in a differentiation process dependent on MAPK/ERK signaling. Here, we identify microRNA-181a as a key modulator of human γδ T cell differentiation. We observe that miR-181a is highly expressed in patients with prostate cancer and that this pattern associates with lower expression of NKG2D, a critical mediator of cancer surveillance. Interestingly, miR-181a expression negatively correlates with an activated type 1 effector profile obtained from in vitro differentiated γδ T cells and miR-181a overexpression restricts their levels of NKG2D and TNF-α. Upon in silico analysis, we identify two miR-181a candidate targets, Map3k2 and Notch2, which we validate via overexpression coupled with luciferase assays. These results reveal a novel role for miR-181a as critical regulator of human γδ T cell differentiation and highlight its potential for manipulation of γδ T cells in next-generation immunotherapies.
(© 2021 The Authors. Published under the terms of the CC BY 4.0 license.)
References: Immunity. 2007 Aug;27(2):334-48. (PMID: 17656116)
Sci Immunol. 2018 May 4;3(23):. (PMID: 29728425)
Proc Natl Acad Sci U S A. 2013 Apr 30;110(18):7407-12. (PMID: 23589855)
Int J Cancer. 2015 Sep 15;137(6):1516-8. (PMID: 25758934)
Transcription. 2017 Jan;8(1):61-66. (PMID: 28027012)
Trends Immunol. 2015 Dec;36(12):802-814. (PMID: 26617322)
Sci Rep. 2017 Mar 24;7:45197. (PMID: 28338079)
Nucleic Acids Res. 2019 Jan 8;47(D1):D155-D162. (PMID: 30423142)
Immunology. 2002 Jun;106(2):127-38. (PMID: 12047742)
Gynecol Oncol. 2015 Apr;137(1):143-51. (PMID: 25579119)
J Immunol. 1995 Jun 1;154(11):5832-41. (PMID: 7538532)
J Immunol. 2008 Nov 15;181(10):7131-7. (PMID: 18981134)
Immunol Cell Biol. 2016 Sep;94(8):741-6. (PMID: 27089939)
Front Immunol. 2017 Oct 27;8:1401. (PMID: 29163482)
Stem Cell Reports. 2017 Apr 11;8(4):1046-1061. (PMID: 28330621)
Nucleic Acids Res. 2014 Jan;42(Database issue):D68-73. (PMID: 24275495)
J Immunol. 2005 Sep 1;175(5):2843-50. (PMID: 16116170)
FEBS Lett. 2003 Jul 3;546(1):37-44. (PMID: 12829234)
EJIFCC. 2019 Jun 24;30(2):114-127. (PMID: 31263388)
Am J Hematol. 2015 Nov;90(11):998-1007. (PMID: 26223969)
Nucleic Acids Res. 2018 Sep 19;46(16):8232-8244. (PMID: 29931229)
FEBS J. 2018 Mar;285(6):1033-1050. (PMID: 29399967)
Eur J Immunol. 2009 Jul;39(7):1794-806. (PMID: 19544311)
Immunity. 2011 Feb 25;34(2):201-12. (PMID: 21333552)
Front Immunol. 2015 Sep 10;6:442. (PMID: 26441956)
Nat Immunol. 2016 Jan;17(1):95-103. (PMID: 26523864)
Cell Mol Immunol. 2019 Feb;16(2):112-125. (PMID: 29429995)
Immunol Rev. 2020 Nov;298(1):47-60. (PMID: 33191519)
Nat Rev Cancer. 2019 Jul;19(7):392-404. (PMID: 31209264)
J Immunol. 2013 Mar 1;190(5):2403-14. (PMID: 23355732)
J Mol Med (Berl). 2020 Feb;98(2):309-320. (PMID: 32002568)
Oncotarget. 2015 Sep 8;6(26):21787-8. (PMID: 26318426)
Nat Med. 2015 Aug;21(8):938-945. (PMID: 26193342)
J Invest Dermatol. 2003 May;120(5):829-34. (PMID: 12713589)
Nat Rev Immunol. 2015 Nov;15(11):683-91. (PMID: 26449179)
Oncotarget. 2014 Jul 30;5(14):5439-52. (PMID: 24978137)
Immunity. 2007 Jul;27(1):89-99. (PMID: 17658279)
PLoS One. 2015 Dec 16;10(12):e0145010. (PMID: 26673421)
Gastric Cancer. 2012 Oct;15(4):433-9. (PMID: 22252158)
Cells. 2020 Mar 26;9(4):. (PMID: 32225004)
Eur J Immunol. 2011 Jan;41(1):195-201. (PMID: 21182090)
Nat Rev Immunol. 2011 Apr;11(4):239-50. (PMID: 21436836)
Exp Hematol. 2009 Jul;37(7):838-48. (PMID: 19446661)
J Immunol. 2012 Apr 1;188(7):3257-67. (PMID: 22379031)
Nat Commun. 2020 Feb 20;11(1):968. (PMID: 32080184)
EMBO Rep. 2022 Jan 5;23(1):e52234. (PMID: 34821000)
J Clin Invest. 2017 Oct 2;127(10):3702-3716. (PMID: 28872459)
Neuro Oncol. 2009 Aug;11(4):357-67. (PMID: 19211933)
Oncol Rep. 2018 Jul;40(1):272-282. (PMID: 29767245)
J Immunol. 2016 May 1;196(9):3927-34. (PMID: 27009493)
J Biol Chem. 2001 May 4;276(18):14784-90. (PMID: 11278622)
J Immunol. 2014 Mar 1;192(5):2237-43. (PMID: 24489097)
Cancer Res. 2013 Oct 15;73(20):6137-48. (PMID: 23959855)
J Immunol. 2011 Nov 15;187(10):4979-86. (PMID: 21987661)
Oncoimmunology. 2015 Jan 07;4(3):e988460. (PMID: 25949900)
Sci Transl Med. 2019 Oct 9;11(513):. (PMID: 31597756)
Genes Dev. 2007 Mar 1;21(5):578-89. (PMID: 17344418)
Immunity. 2014 May 15;40(5):785-800. (PMID: 24816404)
J Hum Genet. 2018 Oct;63(10):1015-1028. (PMID: 30082847)
J Immunol. 2014 Mar 1;192(5):2054-62. (PMID: 24489102)
Proc Natl Acad Sci U S A. 2014 Aug 26;111(34):E3562-70. (PMID: 25114209)
Immunity. 2019 Apr 16;50(4):924-940. (PMID: 30995507)
J Immunol. 2012 Nov 15;189(10):5029-36. (PMID: 23034170)
J Exp Med. 2003 Aug 4;198(3):391-7. (PMID: 12900516)
Cell. 2007 Apr 6;129(1):147-61. (PMID: 17382377)
Science. 2010 Jan 8;327(5962):198-201. (PMID: 19965718)
Leukemia. 2012 Jan;26(1):127-38. (PMID: 22051534)
Oncoimmunology. 2013 Jan 1;2(1):e22892. (PMID: 23483102)
Nature. 2004 Sep 16;431(7006):350-5. (PMID: 15372042)
Int J Cancer. 2006 Nov 15;119(10):2359-65. (PMID: 16929491)
Cell Mol Immunol. 2019 May;16(5):430-441. (PMID: 30778167)
PLoS Genet. 2012;8(8):e1002855. (PMID: 22916024)
Nat Struct Mol Biol. 2010 Jan;17(1):17-23. (PMID: 19966796)
Immunol Cell Biol. 2019 Feb;97(2):190-202. (PMID: 30291723)
Blood. 2010 Mar 25;115(12):2407-11. (PMID: 20101024)
Cancer Res. 2010 Dec 15;70(24):10024-7. (PMID: 21159627)
Nat Immunol. 2009 Apr;10(4):427-36. (PMID: 19270712)
Front Immunol. 2019 Oct 23;10:2520. (PMID: 31708931)
Nat Immunol. 2021 Jul;22(7):914-927. (PMID: 34099919)
Eur J Immunol. 2014 Jul;44(7):1886-95. (PMID: 24782159)
Proc Natl Acad Sci U S A. 2009 Feb 3;106(5):1502-5. (PMID: 19164563)
Nat Immunol. 2008 Oct;9(10):1140-7. (PMID: 18724371)
فهرسة مساهمة: Keywords: cancer; effector T lymphocytes; miR-181a; microRNAs; γδ T cells
المشرفين على المادة: 0 (MIrn181 microRNA, human)
0 (MicroRNAs)
0 (NOTCH2 protein, human)
0 (Receptor, Notch2)
EC 2.7.11.25 (MAP Kinase Kinase Kinase 2)
EC 2.7.11.25 (MAP3K2 protein, human)
تواريخ الأحداث: Date Created: 20211125 Date Completed: 20220314 Latest Revision: 20231105
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC8728617
DOI: 10.15252/embr.202052234
PMID: 34821000
قاعدة البيانات: MEDLINE
الوصف
تدمد:1469-3178
DOI:10.15252/embr.202052234